DETERMINING CANINE proBNP

• US 20090170137A1
• Filed: 02/27/2009
• Published: 07/02/2009
• Est. Priority Date: 09/08/2004
• Status: Abandoned Application

• Current Assignee: The Antibody Lab GmbH
• Original Assignee: The Antibody Lab GmbH
• Inventors: Hawa, Gerhard, Woloszczuk, Wolfgang
• Application Number:
  US12/394,682
• Publication Number:
  US 20090170137A1
• Time in Patent Office: Days
• US Class Current: 435/7.920
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: G01N 2333/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.

Claims

1. A method of detecting canine proBNP or a fragment thereof in a canine sample comprising

(a) providing a canine sample;

(b) contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP; and

(c) detecting the binding of the antibody to the epitope whereby the canine proBNP or the fragment thereof in the sample is detected.

2. The method of claim 1, wherein the epitope comprises at least 3 amino acids.

3. The method of claim 1, wherein the at least one antibody is polyclonal.

4. The method of claim 1, wherein the at least one antibody is monoclonal.

5. The method of claim 1, wherein the sample is a blood sample or a urine sample.

6. The method of claim 1, wherein detecting the binding of the antibody to the epitope comprises radioimmunoassay, immune binding assay, Western blot, immunohistochemistry, or enzyme immunoassay.

7. The method of claim 1, further comprising determining the concentration of the canine proBNP or fragment thereof in the sample.

8. The method of claim 7, further comprising comparing the concentration of the canine proBNP or fragment thereof in the sample with the concentration of canine proBNP or fragment thereof in a sample from a healthy canine.

9. The method of claim 8, further comprising diagnosing cardiac insufficiency in a canine from which the sample was obtained if the concentration of the canine proBNP or fragment thereof in the sample is higher than the concentration of canine proBNP or fragment thereof in the sample from the healthy canine.

10. The method of claim 1, wherein contacting the sample with the at least one antibody occurs on a solid phase.

11. The method of claim 10, wherein the at least one antibody is bound to a solid phase.

12. The method of claim 10, wherein the canine proBNP or fragment thereof is bound to a solid phase.

13. An isolated antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP.

14. The antibody of claim 13, wherein the epitope comprises at least 3 amino acids in the region from amino acids 1 to 22 of canine proBNP.

15. A kit for detecting canine proBNP or a fragment thereof comprising an antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP and a label.

16. The kit of claim 15, wherein the label is peroxidase, biotin, fluorescent dye, gold colloid, or a radionuclide.

17. The kit of claim 15, further comprising a peptide comprising amino acids 1 to 22 of canine proBNP.

18. The kit of claim 15, further comprising at least one further antibody.

19. The kit of claim 18, wherein the at least one further antibody is labeled.

20. The kit of claim 15, wherein the antibody is bound to a solid phase.